For further details see:
Camurus gets positive EMA opinion for Buvidal marketing authorizationhome / stock / camrf / camrf news
For further details see:
Camurus gets positive EMA opinion for Buvidal marketing authorizationMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Camurus AB Company Name:
CAMRF Stock Symbol:
Market:
The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence PR Newswire LUND, Sweden , May 3, 2021 /PRNewswire/ -- Camurus AB (NASDAQ STO: CAMX) today announced that the Australian regulatory agency, the Therapeutic Good...
Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence PR Newswire LUND, Sweden , March 26, 2021 /PRNewswire/ -- Camurus today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Eu...
Once-weekly formulation of setmelanotide achieved weight loss efficacy comparable to daily-dosing formulation Both weekly and daily formulations of setmelanotide were observed to be safe and well-tolerated LUND, Sweden , June 24, 2020 /PRNewswire/ -- Camurus' partner Rhyt...